Learn about our Series A funding and enjoy an old-school pic of Neil and Jimmy.
At Totus Medicines, we are on a mission to develop breakthrough treatments for diseases that are currently untreatable. We are using a new platform technology to discover covalent drugs, which are small molecules that form a covalent bond with their target proteins, preventing them from working.
Covalent drugs have the potential to be very effective against a wide range of diseases, including cancer, heart disease, and neurodegeneration. However, they have been difficult to develop due to their potential for toxicity. Our platform technology is designed to overcome these challenges and develop covalent drugs that are safe and effective.
Our lead drug candidate, TOS-358, is a targeted therapy for the PI3Kα oncogene implicated in various cancers. TOS-358 has shown promising results in preclinical studies, and we plan to initiate clinical trials in 2022.
In addition to cancer, we are also developing covalent drugs for other diseases, including heart disease and neurodegeneration. We are committed to bringing new hope to patients with diseases that are currently untreatable.
Why Totus Medicines is a Promising Investment
There are several reasons why Totus Medicines is a promising investment:
- We have a strong team of experienced scientists and entrepreneurs with a deep understanding of drug discovery and development.
- We have a disruptive technology that has the potential to revolutionize the way that covalent drugs are discovered and developed.
- We are targeting a large and underserved market of patients with diseases that are currently untreatable.
We are excited to be at the forefront of this new wave of innovation in drug discovery. Our platform technology has the potential to develop a new generation of drugs that can treat diseases that are currently untreatable. We are committed to bringing new hope to patients and their families.